Clinical Trial: Efficacy, Safety, and ToLerability of Switching to A Two-Drug Regimen With DTG/3TC Compared to Maintaining A Three-Drug REgimen With BIC/FTC/TAF or DTG/3TC/ABC in ViroLogically SupprEssed PeopLe Living With HIV After 24 and 48 Weeks of Follow-Up

U.S., Aug. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07138144) titled 'Efficacy, Safety, and ToLerability of Switching to A Two-Drug Regimen With DTG/3TC Compared to Maintaining A Three-Drug REgimen With BIC/FTC/TAF or DTG/3TC/ABC in ViroLogically SupprEssed PeopLe Living With HIV After 24 and 48 Weeks of Follow-Up' on Aug. 04.

Brief Summary: This is a phase 4, randomized, controlled, open-label, single-center clinical trial conducted at the Hospital de Infectologia, National Medical Center "La Raza." The study employs a non-inferiority design with follow-up assessments at 24 and 48 weeks. The study will enroll 156 PLWH aged >=18 years who are on ART with BIC/FTC/TAF or DTG/3TC/ABC and have maintained ...